Saturday 17 October 2026
Export NEUP’s income statement to Excel — free account
Neuphoria Therapeutics Inc.
NEUP Healthcare Biotechnology
Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025. In the quarter to June 2026, revenue fell 107.3%, EPS grew 83.6% and free cash flow grew 133.9%, each against the same quarter a year earlier.
3.30
0.01
−0.30%
Follow NEUP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (61.70%) | (62.90%) | (26.07%) | (64.04%) |
+8 more TTM periods Free account |
|
| (46.95%) | (53.21%) | (20.68%) | (37.69%) | ||
ROIC |
(232.67%) | (104.93%) | (29.96%) | 0.00% | |
Return on Tangible Assets |
(66.23%) | (86.53%) | (27.23%) | (107.26%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.81) | (3.17) | (0.52) | 0.32 | |
Free Cash Flow |
(12.35) | (17.15) | (2.36) | 0.72 | |
| Other line items | |||||
Cash ROIC |
(27.78%) | (35.10%) | (4.55%) | 2.73% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.01) | (0.02) | (0.07) | (0.04) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.92 | 0.98 | 0.42 | (0.08) | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 255.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.81) | (3.17) | (0.52) | 0.32 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026